These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28586949)

  • 21. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
    Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study.
    Lombardi G; Bergo E; Del Bianco P; Bellu L; Pambuku A; Caccese M; Trentin L; Zagonel V
    Am J Clin Oncol; 2018 Dec; 41(12):1263-1271. PubMed ID: 29750673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
    Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
    J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
    Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
    Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
    Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
    Kickingereder P; Hamisch C; Suchorska B; Galldiks N; Visser-Vandewalle V; Goldbrunner R; Kocher M; Treuer H; Voges J; Ruge MI
    J Neurooncol; 2014 Dec; 120(3):615-23. PubMed ID: 25151509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.
    Erpolat OP; Akmansu M; Goksel F; Bora H; Yaman E; Büyükberber S
    Tumori; 2009; 95(2):191-7. PubMed ID: 19579865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
    N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
    Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM
    Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.